Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDA Modernization Act: implications for oncology.

L Morris1

  • 1Consulting Divisions, PRR, Inc., Melville, New York, USA.

Oncology (Williston Park, N.Y.)
|February 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TB programme outcomes in South Fly District, Papua New Guinea, were maintained through COVID-19.

Public health action·2024
Same author

Widening the gap: could residential 'simulated altitude prehabilitation' exacerbate health inequalities?

Anaesthesia·2024
Same author

Reliability and validity testing of the ASSIST functional performance index.

Assistive technology : the official journal of RESNA·2023
Same author

The impact of compliance on Stage 2 uni-ventricular heart circulation: An experimental assessment of the Bidirectional Glenn.

Medical engineering & physics·2020
Same author

Palliative Radiation Therapy in Older Adults With Cancer: Age-Related Considerations.

Clinical oncology (Royal College of Radiologists (Great Britain))·2020
Same author

Advances in the Direct Study of Carbon Burning in Massive Stars.

Physical review letters·2020

The Food and Drug Administration (FDA) Modernization Act enhances drug accessibility and information dissemination. It streamlines approval processes and expands patient access to novel cancer treatments and clinical trial data.

Area of Science:

  • Regulatory Science
  • Oncology
  • Pharmaceutical Policy

Background:

  • The Food and Drug Administration (FDA) Modernization Act of 1997 significantly revised regulations for prescription drug approval, labeling, and promotion.
  • Key provisions impact oncologists' and patients' access to novel cancer therapies and related information.

Purpose of the Study:

  • To analyze the major impacts of the FDA Modernization Act on drug approval and patient access in oncology.
  • To highlight changes in drug review funding, approval flexibility, clinical trial data access, and information dissemination.

Main Methods:

  • Review of the legislative text and stated impacts of the FDA Modernization Act.
  • Analysis of how specific sections influence drug approval pathways and information availability for cancer treatments.

Related Experiment Videos

Main Results:

  • Continued FDA funding ensures a steady supply of new drugs for disease prevention and treatment.
  • Increased flexibility in drug approval, including single-trial approvals and "fast track" designations based on surrogate endpoints.
  • Improved access to investigational products through a clinical trials databank and emergency use authorization.
  • Relaxed restrictions on drug company dissemination of health, economic, and off-label use information, while incentivizing new use investigations.

Conclusions:

  • The FDA Modernization Act facilitates faster access to innovative cancer treatments for patients.
  • Enhanced information sharing and streamlined approval processes benefit both healthcare providers and patients in oncology.
  • The act balances the need for timely drug access with continued incentives for pharmaceutical research and development.